View All Abstracts for Session 46
251 New Database for SIV/HIV/SHIV Vaccines in Nonhuman Primate Models
J. L. K. Mokili*1, R. Funkhouser1,2, J. Warren3, C. Kuiken1, and B. T. Korber1,2
1Los Alamos Natl. Lab., NM, USA; 2Santa Fe Inst., NM, USA; and 3 NIAID, NIH, Bethesda, MD, USA
Background: The urgency for the development of effective vaccine(s) against HIV-1 has motivated many research teams to study different SIV, HIV, and SHIV vaccines in nonhuman primates. To allow comparison of data, given the differences in the nature of the vaccines and methods, a relational database is under development at the Los Alamos National Laboratory. The database will provide access to both summaries and detailed data from past and ongoing vaccine trials through a web interface (website: http://hiv-vacdb.lanl.gov/).
Database design: The database will be developed using Sybase and principles used to construct the HIV sequence and immunology databases. Data will be obtained from the literature and, when possible augmented with more recent data from ongoing studies. The working design will allow information to be retrieved by searching for specific fields, including but not limited to trial, type of vaccine, strains used to construct vaccine, challenge strain, route of vaccination, route and dose of challenge, immunization schedule, adjuvant, monkey species, and HLA classes. Vaccination outcome parameters will include: reduction in viral load, maintenance of baseline CD4 count, clinical signs and symptoms, and period of follow-up. Host immunologic parameters will include: antibody titers, binding and neutralization, epitope recognition, and cellular responses including T-cell proliferation and CTL. An effort will be made to augment the database with more detailed information about outcome parameters, and to organize the data in a simpler and more intuitive way. The quality of the data may be ensured by double data entry and will be critically reviewed by the Los Alamos database staff for accuracy. Meta-analysis of combined studies will be conducted, where appropriate, and the results will be reported on the website and in peer-reviewed journals. Links will be created to other databases and resources, including PubMed and the nucleotide sequence and immunology database, as well as a new database of HLA data.
Conclusions: The new database will increase accessibility and utility of nonhuman primate vaccine trials and will permit further integration of these data into the overall HIV-1 vaccine effort.
Contact Author about this Abstract
